• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
NAMZARIC Drug Profile, 2024: NAMZARIC (donepezil hydrochloride; memantine hydrochloride) drug patents, FDA exclusivity, litigation, drug prices

NAMZARIC Drug Profile, 2024: NAMZARIC (donepezil hydrochloride; memantine hydrochloride) drug patents, FDA exclusivity, litigation, drug prices

Paperback

Series: Drugpatentwatch Business Intelligence Reports

Medical Reference

Currently unavailable to order

ISBN13: 9798875703607
Publisher: Independently Published
Published: Jan 10 2024
Pages: 110
Weight: 0.60
Height: 0.23 Width: 8.50 Depth: 11.00
Language: English
NAMZARIC Drug Profile, 2024

This report focuses on NAMZARIC and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • Patent Trial and Appeal Board (PTAB) patent cases
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers
  • Raw active pharmaceutical ingredient (API) sources
FREE UPDATE: Send your receipt to DrugPatentWatch within 30 days for a free updat

Also in

Medical Reference